Acute leukemia is a fast-moving blood cancer in which the bone marrow produces large numbers of abnormal, immature white blood cells called blasts. These blasts crowd out healthy blood cells, leading to rapid bone marrow failure. Unlike chronic leukemia, which progresses slowly over months or years, acute leukemia worsens within weeks and requires prompt treatment.
How Acute Leukemia Develops
Your bone marrow normally produces a steady supply of red blood cells, white blood cells, and platelets. In acute leukemia, a genetic change in an early blood cell causes it to multiply uncontrollably while failing to mature into a functional cell. These immature cells, the blasts, accumulate in the marrow and spill into the bloodstream. Because the blasts take up space and resources, the marrow can no longer make enough red blood cells to carry oxygen, enough platelets to control bleeding, or enough normal white blood cells to fight infection.
A diagnosis typically requires that at least 20% of the cells in the bone marrow are blasts (in a healthy person, that number is under 5%). Some newer classification systems lower that threshold to 10% when specific genetic mutations are present.
The Two Main Types
Acute leukemia is divided into two broad categories based on which cell line is affected:
- Acute myeloid leukemia (AML) starts in cells that would normally become red blood cells, platelets, or certain types of white blood cells. It is far more common in adults, with most cases diagnosed after age 65.
- Acute lymphoblastic leukemia (ALL) starts in cells destined to become lymphocytes, a type of white blood cell central to the immune system. ALL is the most common cancer in children, though it also occurs in adults.
The distinction matters because the two types respond to different treatments. ALL cells, for example, often depend on a nutrient called asparagine that they cannot produce on their own, which is why a therapy that depletes asparagine has been a cornerstone of ALL treatment for decades. AML cells have different vulnerabilities tied to how they generate energy, and treatment strategies reflect that biology.
Symptoms and How Quickly They Appear
Because acute leukemia disrupts normal blood cell production so rapidly, symptoms tend to show up over days to weeks rather than gradually. Many of them mimic the flu or other common illnesses, which is why early leukemia is easy to miss. The most common signs include:
- Persistent fatigue and weakness (from low red blood cells)
- Frequent or severe infections, fever, or chills (from low functional white blood cells)
- Easy bruising, tiny red skin spots called petechiae, or recurrent nosebleeds (from low platelets)
- Unexplained weight loss
- Bone pain or tenderness
- Swollen lymph nodes, or a feeling of fullness from an enlarged spleen or liver
- Heavy night sweats
None of these symptoms alone points to leukemia, but several appearing together and worsening quickly is a pattern worth taking seriously. A routine blood test showing abnormal counts is often the first concrete clue.
Risk Factors
Most people diagnosed with acute leukemia have no obvious cause, but several factors raise risk. Age is the strongest one for AML: survival drops significantly in patients over 65 even with intensive treatment. Male sex and obesity are also associated with higher rates.
Among environmental exposures, benzene is one of the best-established triggers. A large population-based study found that people exposed to benzene had roughly twice the odds of developing AML compared to unexposed individuals. Exposure to coal dust, soot, creosote, and vinyl chlorides carried similar or even higher risks. Prior chemotherapy, particularly with a class of drugs called alkylating agents, and previous radiation therapy can also cause secondary acute leukemia years after the original cancer treatment. Cigarette smoking rounds out the list of well-documented risk factors.
How It Is Diagnosed
Diagnosis starts with a complete blood count, but confirming acute leukemia and identifying its exact subtype requires more specialized testing. A bone marrow biopsy provides the sample, and from there several tools come into play.
Flow cytometry is one of the most important. It works by passing individual cells through a laser beam after they have been tagged with fluorescent markers that stick to specific surface proteins. This lets pathologists rapidly identify which cell line the blasts belong to, whether myeloid or lymphoid, and further classify the subtype. Genetic testing, known as cytogenetic analysis, examines the chromosomes inside the leukemia cells for rearrangements, deletions, or extra copies. These genetic findings are critical because they determine both the subtype and the risk category, which in turn shapes the treatment plan.
For example, a translocation between chromosomes 15 and 17 identifies acute promyelocytic leukemia, a subtype with a cure rate above 95% using modern therapy. A mutation in the FLT3 gene, on the other hand, signals a more aggressive form that may benefit from targeted drugs or a stem cell transplant.
Treatment Phases
Treatment for acute leukemia generally unfolds in two main phases. The first, called induction, aims to destroy the leukemia cells in the blood and bone marrow and achieve remission, meaning blasts fall below detectable levels. Induction typically involves intensive chemotherapy given in the hospital over several weeks. It is physically demanding: the drugs suppress the entire bone marrow temporarily, so patients are vulnerable to infection and bleeding during this period.
The second phase, consolidation, begins once remission is confirmed. Its goal is to eliminate any remaining leukemia cells that could trigger a relapse. Consolidation may involve additional rounds of chemotherapy, and for patients with higher-risk genetic profiles, it often includes a stem cell transplant.
The decision to pursue a transplant depends heavily on the genetic risk of relapse. Patients whose leukemia carries favorable genetic markers, where the chance of relapse is roughly 35 to 40%, may do well with chemotherapy alone. Those with high-risk genetics face a 70 to 80% chance of relapse without a transplant, making it the only realistic path to long-term remission for many of them. For patients over 65, fewer than 20% survive five years with chemotherapy alone, so transplant using reduced-intensity conditioning is increasingly considered regardless of strict age cutoffs.
Targeted Therapies
Chemotherapy remains the backbone of treatment, but targeted drugs are now part of standard care for certain genetic subtypes. Patients with FLT3 mutations, one of the most common genetic changes in AML, can receive drugs that specifically block the overactive FLT3 protein. These are given alongside chemotherapy for newly diagnosed patients or as standalone treatment when the disease comes back after initial therapy.
These targeted approaches are not a replacement for chemotherapy in most cases, but they improve response rates for the patients who qualify. Genetic testing at diagnosis determines eligibility.
Survival Rates
Survival varies dramatically depending on the type of leukemia, the patient’s age, and the genetic profile of the cancer. For AML across all ages, the overall five-year survival rate is about 33%. That number, though, masks wide variation. Children with ALL have five-year survival rates above 90% with modern treatment, while older adults with AML fare significantly worse.
Genetic subtype is one of the strongest predictors. Acute promyelocytic leukemia is curable in over 95% of cases. AML with a monosomal karyotype, one of the highest-risk categories, has a relapse rate above 90% without a transplant.
Complications to Be Aware Of
Acute leukemia can cause life-threatening complications both before and during treatment. One of the most serious is tumor lysis syndrome, which happens when large numbers of cancer cells break apart rapidly, usually after chemotherapy begins. The dying cells dump their contents into the bloodstream, causing dangerous spikes in potassium, phosphate, and uric acid. This can lead to kidney failure, heart rhythm problems, and in severe cases, death. In one study of 772 AML patients, 17% developed tumor lysis syndrome during treatment, and among the subset with the most severe form, 79% died during induction.
Patients with extremely high white blood cell counts, above 100,000 per microliter, are at the highest risk. Treatment teams monitor lab values closely and often give preventive fluids and medications before chemotherapy starts to reduce this danger.